{"title":"Metabolomics of Osteoporosis in Humans: A Systematic Review.","authors":"Kat-Tik Lau, Suhas Krishnamoorthy, Chor-Wing Sing, Ching Lung Cheung","doi":"10.1007/s11914-023-00785-8","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose of review: </strong>To systematically review recent studies investigating the association between metabolites and bone mineral density (BMD) in humans.</p><p><strong>Methods: </strong>Using predefined keywords, we searched literature published from Jan 1, 2019 to Feb 20, 2022 in PubMed, Web of Science, Embase, and Scopus. Studies that met the predefined exclusion criteria were excluded. Among the included studies, we identified metabolites that were reported to be associated with BMD by at least three independent studies.</p><p><strong>Recent findings: </strong>A total of 170 studies were retrieved from the databases. After excluding studies that did not meet our predefined inclusion criteria, 16 articles were used in this review. More than 400 unique metabolites in blood were shown to be significantly associated with BMD. Of these, three metabolites were reported by ≥ 3 studies, namely valine, leucine and glycine. Glycine was consistently shown to be inversely associated with BMD, while valine was consistently observed to be positively associated with BMD. Inconsistent associations with BMD was observed for leucine. With advances in metabolomics technology, an increasing number of metabolites associated with BMD have been identified. Two of these metabolites, namely valine and glycine, were consistently associated with BMD, highlighting their potential for clinical application in osteoporosis. International collaboration with a larger population to conduct clinical studies on these metabolites is warranted. On the other hand, given that metabolomics could be affected by genetics and environmental factors, whether the inconsistent association of the metabolites with BMD is due to the interaction between metabolites and genes and/or lifestyle warrants further study.</p>","PeriodicalId":11080,"journal":{"name":"Current Osteoporosis Reports","volume":"21 3","pages":"278-288"},"PeriodicalIF":4.2000,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Osteoporosis Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11914-023-00785-8","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 1
Abstract
Purpose of review: To systematically review recent studies investigating the association between metabolites and bone mineral density (BMD) in humans.
Methods: Using predefined keywords, we searched literature published from Jan 1, 2019 to Feb 20, 2022 in PubMed, Web of Science, Embase, and Scopus. Studies that met the predefined exclusion criteria were excluded. Among the included studies, we identified metabolites that were reported to be associated with BMD by at least three independent studies.
Recent findings: A total of 170 studies were retrieved from the databases. After excluding studies that did not meet our predefined inclusion criteria, 16 articles were used in this review. More than 400 unique metabolites in blood were shown to be significantly associated with BMD. Of these, three metabolites were reported by ≥ 3 studies, namely valine, leucine and glycine. Glycine was consistently shown to be inversely associated with BMD, while valine was consistently observed to be positively associated with BMD. Inconsistent associations with BMD was observed for leucine. With advances in metabolomics technology, an increasing number of metabolites associated with BMD have been identified. Two of these metabolites, namely valine and glycine, were consistently associated with BMD, highlighting their potential for clinical application in osteoporosis. International collaboration with a larger population to conduct clinical studies on these metabolites is warranted. On the other hand, given that metabolomics could be affected by genetics and environmental factors, whether the inconsistent association of the metabolites with BMD is due to the interaction between metabolites and genes and/or lifestyle warrants further study.
综述的目的:系统地回顾最近研究代谢物与人类骨密度(BMD)之间关系的研究。方法:使用预定义关键词检索PubMed、Web of Science、Embase和Scopus中2019年1月1日至2022年2月20日发表的文献。符合预定排除标准的研究被排除。在纳入的研究中，我们确定了至少三个独立研究报告的与BMD相关的代谢物。最新发现:从数据库中检索了170项研究。在排除了不符合预定纳入标准的研究后，本综述共纳入了16篇文章。血液中超过400种独特的代谢物被证明与骨密度显著相关。其中，有3项研究报道了3种代谢物，即缬氨酸、亮氨酸和甘氨酸。甘氨酸一直被证明与骨密度呈负相关，而缬氨酸一直被认为与骨密度呈正相关。亮氨酸与骨密度的关系不一致。随着代谢组学技术的进步，越来越多的与BMD相关的代谢物被发现。其中两种代谢物，即缬氨酸和甘氨酸，一直与BMD相关，突出了它们在骨质疏松症的临床应用潜力。有必要与更大的人群进行国际合作，对这些代谢物进行临床研究。另一方面，鉴于代谢组学可能受到遗传和环境因素的影响，代谢物与骨密度的不一致关联是否由于代谢物与基因和/或生活方式之间的相互作用，值得进一步研究。
期刊介绍：
This journal intends to provide clear, insightful, balanced contributions by international experts that review the most important, recently published clinical findings related to the diagnosis, treatment, management, and prevention of osteoporosis.
We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as current and future therapeutics, epidemiology and pathophysiology, and evaluation and management. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
